Post Profile

MicroRNA Specifically Kills Cancer Cells with Common Mutation

Approximately 20 percent of all human cancers have mutations in a gene called KRAS. KRAS-mutant cancers are among the most difficult to treat, with poor survival and resistance to chemotherapy. Researchers at University of California San Diego School of Medicine and Moores Cancer Center used microRNAs to systematically inhibit thousands of other genes to find combinations that are specifically lethal to cancer cells driven by a KRAS mutation.
read more


Related Posts

New Subsets of Lung Cancer with KRAS Gene Mutations Identified

Health : Newswise Medical News

Mutations of the KRAS gene are commonly known to lead to cancer. However, deeper understanding of exactly how they do this continues to be explored by cancer researchers.

Scientists Discover New Therapeutic Target for Lung Cancer Driven by KRAS

Health : Newswise Medical News

UT Southwestern Medical Center researchers have identified a new way to target lung cancer through the KRAS gene, one of the most commonly mutated genes in human cancer and one researchers have so far had difficulty targeting succes...

Hope for development of drugs to stall the growth of K-Ras cancers, previously deemed impossible to treat

Health : Medical News Today

NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies to th...

UT Southwestern Cancer Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation Involved in Lung, Colon, and Pancreatic Cancers

Health : Newswise Medical News

UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors.

$250K Grant Supports Examination of Drug Compound on Common Cancer Mutation

Health : Newswise Medical News

A $250,000 grant from the Breast Cancer Research Foundation awarded to a Rutgers Cancer Institute of New Jersey researcher will help further elucidate the inner workings of the p53 gene. The work will examine a drug compound that re...


Copyright © 2016 Regator, LLC